Johnson & Johnson and Progressive Corporation reported strong Q2 earnings in July 2025.
1 report, 1 independent
Updated Jul 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Johnson & Johnson and Progressive Corporation reported strong Q2 earnings in July 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Progressive Corporation
insurance company
Related events
- Johnson & Johnson, BDX, and Universal Health Realty Income Trust were identified as attractive dividend-paying healthcare stocks.
- Johnson & Johnson and PepsiCo were classified as elite Dividend Kings and featured as attractive dividend stocks.
- Johnson & Johnson and Realty Income are noted for competing dividend investment vehicles.
- Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
Coverage
Newest first; wire copies grouped- ZacksCompany News for Jul 17, 2025 Shares of Johnson & Johnson (JNJ) jumped 6.2% after the company reported second-quarter 2025 earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 p